x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

business

All Episodes

23:08

306: Live! From the STAT Breakthrough Summit West

The Readout Loud ·

2024/05/16

On this week’s "Readout LOUD," we’re live in San Francisco at STAT’s Breakthrough Summit West. AI is a big theme this year, everywhere, so on that note, we chat with our AI correspondent — and recent Pulitzer finalist — Casey Ross, who sat down on stage to discuss AI-centered drug discovery with both NVIDIA and Google-backed Isomorphic Labs. We also discuss this week’s biotech news, including yet more obesity drug data, this time from Roche, and the closing of Novartis’ acquisition of MorphoSys.

en

31:52

305: Everything you need to know about H5N1 bird flu

The Readout Loud ·

2024/05/09

This week on "The Readout LOUD," STAT senior infectious diseases reporter Helen Branswell walks us through ongoing H5N1 outbreak in the U.S. and issues with monitoring the spread. And in a bit of shameless self-promotion, we’ll talk to our colleagues Bob Herman and Casey Ross about being named Pulitzer finalists in investigative reporting for their reporting on United Healthcare’s use of algorithms in coverage decisions. We'll hear what’s happened since their explosive work was published last

en

33:04

304: Controversial brain tissue research, obesity...

The Readout Loud ·

2024/05/02

The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins “The Readout LOUD” podcast to discuss the results of a two-year investigation. We also discuss Novartis’ effort to acquire MorphoSys, and the latest news on Eli

en

31:45

303: A new obesity startup, an acquisition gone...

The Readout Loud ·

2024/04/18

We bring on biotech veteran Clive Meanwell to discuss his new obesity startup, Metsera, and running head-to-head trials against Wegovy and Zepbound. We also dissect how Teledoc CEO Jason Gorevic parted ways with the company after spending 15 years building the telemedicine field.Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care

en

24:48

302: Vertex's big deal, biotech's red numbers, & an...

The Readout Loud ·

2024/04/11

How would you spend $13 billion in cash? Is biotech stale? And remember Dendreon?We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss a multibillion-dollar deal from Vertex Pharmaceuticals with sweeping implications and a lengthy backstory. We also explain why gas prices are weighing on biotech, and make a surprise announcement.

en

31:37

301: Biotech mega-rounds, a cancer vaccine setback &...

The Readout Loud ·

2024/04/04

Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use case for GLP-1s, and a hurdle in Verve’s gene editing plans. Here’s where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner

en

34:21

300: What the mifepristone case means, GLP-1...

The Readout Loud ·

2024/03/28

Our colleague Sarah Owermohle joins us to explain the Supreme Court case that could have dramatic effects on access to medication abortion — and the development of new medicines. We also discuss the latest news in the life sciences, including a contrarian take on a new obesity treatment, a congressional effort to ban Chinese biotech companies, and how we managed to make 300 episodes of this podcast.Here’s where you can subscribe to our biotech newsletter, The Readout. And here's where you can

en

33:54

299: Live! From the STAT Breakthrough Summit East

The Readout Loud ·

2024/03/21

Recorded live from from the STAT Breakthrough Summit East in New York City, we discuss some event highlights, including words from CRISPR pioneer Feng Zhang and Regeneron Pharmaceuticals head scientist George Yancopoulos. We also discuss the latest news in the life sciences, including a twist in the GLP-1 story, the cost of gene therapy, and, of course, pie.

en

35:21

298: A dilemma in ALS, the first MASH drug, & why...

The Readout Loud ·

2024/03/14

Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.

en

27:11

297: VC turmoil, GLP-1 competition, & the war on...

The Readout Loud ·

2024/03/07

For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives. STAT’s Lev Facher joins us to explain his reporting on why virtually every sector of American society is standing in the way of their use. We also discuss the latest news in the life sciences, including the haves and have-nots of venture capital, and the race to develop effective oral treatments for obesity.

en

24:21

296: Legal insider trading, booming biotech stocks, &...

The Readout Loud ·

2024/02/29

We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it's such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc.

en

34:11

295: Humira’s legacy, CEO symbolism, and genomic surgery

The Readout Loud ·

2024/02/22

First, former Alnylam Pharmaceuticals CEO John Maraganore and STAT’s Matthew Herper join us to discuss the legacy of AbbVie chief executive Richard Gonzalez, who announced his retirement this week. Then, we dive into the fascinating world of fetal genome surgery, as STAT’s Megan Molteni joins us to explain the work of a scientist named Tippi MacKenzie.Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and

en

30:43

294: Pharma goes to Washington, Alnylam's future, &...

The Readout Loud ·

2024/02/15

The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election. We also discuss the latest news in the life sciences, including a twist in the future of Alnylam Pharmaceuticals, competition to Vertex Pharmaceuticals’ pain drug, and Gilead Sciences' latest

en

32:55

293: AI in medicine, detangling hype, and Icelandic DNA

The Readout Loud ·

2024/02/08

It's our all-AI episode. First, STAT’s Casey Ross joins us to explain his reporting on how researchers and pharmaceutical firms are using the technology to find new drug targets, design therapies, and improve clinical trials. Then, we talk to Joel Dudley, a partner at the venture firm Innovation Endeavors, about how to discern promising ideas from wastes of time when it comes to AI in biotech. Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe

en

35:44

292: Vertex's polarizing data, Aduhelm's adieu, & an...

The Readout Loud ·

2024/02/01

We explain the debate over Vertex Pharmaceuticals' novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about the latest news in the life sciences, including an epitaph for Aduhelm and the retirement of an FDA icon. Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc.

en

31:15

291: The plight of the VC, Gilead's latest setback, &...

The Readout Loud ·

2024/01/25

We discuss how biotech's downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. We also take a look at Gilead Sciences' struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm. Subscribe to our biotech newsletter, The Readout.

en

42:49

290: Biotech layoffs, slumping stocks, and a 2024...

The Readout Loud ·

2024/01/18

Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions. Here's where you can subscribe to our biotech newsletter, The Readout.

en

28:14

289: Live! From #JPM24

The Readout Loud ·

2024/01/11

Recording from the STAT co-working space outside the J.P. Morgan Healthcare Conference, we discuss how a spate of deals and some intermittent sunshine seem to have brightened the outlook for biotech at the outset of 2024. We also talk about the latest twist in the Sarepta Therapeutics saga, a ubiquitous dealmaker, and life on the party circuit. For more on what we cover, here's the news on Sarepta; here's more on Nvidia; here's the story on Centerview; here’s where you can find episodes of Color

en

27:21

287: 2023 in review, CEO report cards, and a look at...

The Readout Loud ·

2023/12/21

It's our last episode of 2023, so we look back on the biggest stories of the year, discuss the best and worst CEOs in the industry, and make some reasonably informed guesses on what 2024 has in store for the drug industry.

en

34:49

286: FTC v. biotech, Pfizer's kitchen sink, &...

The Readout Loud ·

2023/12/14

First, we delve into the fallout over the FTC's move to block what looked like a humdrum biotech deal between Sanofi and Maze Therapeutics, a surprising twist that leaves unanswered question. We also discuss the latest news in the life sciences, including Pfizer’s downbeat future, Vertex Pharmaceuticals’ next big thing, and a newly minted biotech VC with a very famous name. Here's where you can subscribe to our biotech newsletter, The Readout.

en

388 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...